“FDA grants priority review for Genentech’s OCREVUS™ (Ocrelizumab) biologics license application”
Read the full press release at: www.gene.com
Genentech has created the first and only treatment for both relapsing (RMS) and primary progression (PPMS) forms of multiple sclerosis (MS). The FDA granted priority review and is fast-tracking OCREVUS™ (Ocrelizumab) in order to help MS patients by the end of this year. OCREVUS™ is the first investigational medicine to receive the Breakthrough Therapy Designation in MS.
Check out an interview about the effectiveness and safety of the treatment with Genentech’s Dr. Peter Chin, a renowned neurologist and principal medical director of Global Neuroscience Development, on Multiple Sclerosis News Today.
In related news, this article, “Exploring Brain Health”, outlines why focusing on brain health is important for everyone – but especially MS patients. Learn more about enriching your brain and gain insights from a man diagnosed over 13 years ago and how brain health has helped support his treatment and management of MS.
Building brain health improves overall well-being!